ES2177817T3 - Procedimiento y composicion mejorados para cisplatina terapeutica (cddp). - Google Patents

Procedimiento y composicion mejorados para cisplatina terapeutica (cddp).

Info

Publication number
ES2177817T3
ES2177817T3 ES96939733T ES96939733T ES2177817T3 ES 2177817 T3 ES2177817 T3 ES 2177817T3 ES 96939733 T ES96939733 T ES 96939733T ES 96939733 T ES96939733 T ES 96939733T ES 2177817 T3 ES2177817 T3 ES 2177817T3
Authority
ES
Spain
Prior art keywords
cisplatin
therapeutic
cddp
composition
improved procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96939733T
Other languages
English (en)
Inventor
Kathleen V Roskos
Richard E Jones
Richard Maskiewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matrix Pharmaceutical Inc
Original Assignee
Matrix Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Pharmaceutical Inc filed Critical Matrix Pharmaceutical Inc
Application granted granted Critical
Publication of ES2177817T3 publication Critical patent/ES2177817T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PROPORCIONA UN DILUYENTE MEJORADO PARA LA PREPARACION DE SUSPENSIONES DE CISPLATINO A PARTIR DE UN POLVO LIOFILIZADO. EL DILUYENTE CONTIENE UN SURFACTANTE NO IONICO FARMACEUTICAMENTE ACEPTABLE, QUE MEJORA LA PRECISION Y LA HOMOGENEIDAD DE LA FORMULACION TERAPEUTICA. LA SUSPENSION PUEDE USARSE DIRECTAMENTE O PARA PREPARAR FORMULACIONES DE GEL PARA SU INYECCION DIRECTA EN UNA LESION NEOPLASICA O EN EL TEJIDO CIRCUNDANTE.
ES96939733T 1995-10-30 1996-10-29 Procedimiento y composicion mejorados para cisplatina terapeutica (cddp). Expired - Lifetime ES2177817T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/550,086 US6077545A (en) 1995-10-30 1995-10-30 Process and composition for therapeutic cisplatin (CDDP)

Publications (1)

Publication Number Publication Date
ES2177817T3 true ES2177817T3 (es) 2002-12-16

Family

ID=24195686

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96939733T Expired - Lifetime ES2177817T3 (es) 1995-10-30 1996-10-29 Procedimiento y composicion mejorados para cisplatina terapeutica (cddp).

Country Status (11)

Country Link
US (2) US6077545A (es)
EP (1) EP0861084B1 (es)
JP (1) JPH11514650A (es)
KR (1) KR100486146B1 (es)
AT (1) ATE219370T1 (es)
AU (1) AU722687B2 (es)
DE (1) DE69621942T2 (es)
DK (1) DK0861084T3 (es)
ES (1) ES2177817T3 (es)
PT (1) PT861084E (es)
WO (1) WO1997016196A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6907679B2 (en) * 1998-11-12 2005-06-21 Qlt Usa, Inc. Method for lyophilizing an active agent
US6722054B2 (en) 1998-11-12 2004-04-20 Atrix Laboratories, Inc. Process and delivery container for lyophilizing active agent
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
IN186588B (es) * 1999-07-28 2001-10-06 Vinod Daftary Gautam Dr
US20040214783A1 (en) 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US6566144B1 (en) * 2000-03-27 2003-05-20 Atrix Laboratories Cover plate for use in lyophilization
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
US9266785B2 (en) 2001-12-20 2016-02-23 Zero Gravity Solutions, Inc. Bioavailable minerals for plant health
US20120171130A1 (en) * 2001-12-20 2012-07-05 John Wayne Kennedy Mitigation of Animal and Plant Diseases Using Bioavailable Minerals
BR0313060A (pt) * 2002-07-29 2005-06-28 Transform Pharmaceuticals Inc Composições farmacêuticas aquosas de 2,6-diisopropilfenol
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
ES2432164T3 (es) 2009-06-04 2013-12-02 Alk Ag Composición estabilizada que comprende al menos un compuesto adrenérgico
US8628805B2 (en) * 2009-06-04 2014-01-14 Alk Ag Stabilized composition comprising at least one adrenergic compound
CA3003183A1 (en) 2015-11-24 2017-06-01 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
EP3411647A4 (en) 2016-02-05 2019-09-25 Tolmar Therapeutics, Inc. VENTED COVER PLATE FOR AN ARRANGEMENT OF SPRAY
US10279192B2 (en) 2016-11-17 2019-05-07 Cognito Therapeutics, Inc. Methods and systems for neural stimulation via visual stimulation
US20200206352A1 (en) * 2017-08-31 2020-07-02 Tohoku University Optimal osmotic range for a drug-containing solution suitable for lymphatic delivery
WO2019067505A1 (en) 2017-09-26 2019-04-04 Ys Pharmtech STABILIZATION OF EPINEPHRINE FORMULATIONS
US10960225B2 (en) 2017-10-10 2021-03-30 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
EP3694464B1 (en) 2017-10-10 2025-12-10 Massachusetts Institute of Technology Systems for preventing, mitigating, and/or treating dementia
BR112020006950A2 (pt) 2017-10-10 2020-10-06 Merck Patent Gmbh composições farmacêuticas injetáveis estabilizadas de l-epinefrina
USD908916S1 (en) 2018-06-19 2021-01-26 Tolmar Therapeutics, Inc. Syringe restrictor plate
EP3586823A1 (en) * 2018-06-25 2020-01-01 CAPNOMED GmbH Therapeutic composition, method and set for providing said therapeutic composition
US20220354794A1 (en) 2019-09-20 2022-11-10 Nivagen Pharmaceuticals, Inc. Lyophilized Compositions of Phenobarbital Sodium Salt
US11406598B2 (en) * 2019-09-20 2022-08-09 Nivagen Pharmaceuticals, Inc. Lyophilized compositions of phenobarbital sodium salt
WO2021216957A1 (en) * 2020-04-23 2021-10-28 Massachusetts Institute Of Technology Systems, devices, and methods for gamma entrainment using sensory stimuli to alleviate cognitive deficits and/or neuroinflammation induced by chemotherapy agents
EP4329778A4 (en) * 2021-04-26 2025-02-19 Crititech, Inc. CISPLATIN PARTICLES AND THEIR USES
CN113995714B (zh) 2021-10-28 2023-04-28 杭州师范大学 一种顺铂交联的蛋白水凝胶及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US5100877A (en) * 1986-05-21 1992-03-31 Kuraray Co., Ltd. Platinum containing pullulan derivatives and pharmaceutical compositions comprising the same
DK86988A (da) * 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
EP0464210A4 (en) * 1989-12-15 1992-11-25 Tsumura & Co. Novel platinum complex and antitumor drug containing the same as active ingredient
NL9000634A (nl) * 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5750146A (en) * 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug

Also Published As

Publication number Publication date
EP0861084B1 (en) 2002-06-19
US6077545A (en) 2000-06-20
AU7682096A (en) 1997-05-22
ATE219370T1 (de) 2002-07-15
DK0861084T3 (da) 2002-10-07
US6224883B1 (en) 2001-05-01
DE69621942D1 (de) 2002-07-25
JPH11514650A (ja) 1999-12-14
DE69621942T2 (de) 2003-01-23
WO1997016196A1 (en) 1997-05-09
AU722687B2 (en) 2000-08-10
KR20000064302A (ko) 2000-11-06
PT861084E (pt) 2002-11-29
KR100486146B1 (ko) 2005-08-05
EP0861084A4 (en) 2000-02-02
EP0861084A1 (en) 1998-09-02

Similar Documents

Publication Publication Date Title
ES2177817T3 (es) Procedimiento y composicion mejorados para cisplatina terapeutica (cddp).
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
PT1412384E (pt) Formulação estável de glp-1 modificado
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
ID27788A (id) Peptida-peptida antigen tumor yang diperoleh dari siklofilin b
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
BRPI0113042B8 (pt) composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
HUT54144A (en) Process for producing 3-desmethylmevalonic acid derivatives and pharmaceutical compositions comprising same as active ingredient
NZ503830A (en) Papilloma virus capsomere vaccine formulations and methods of use
BR0007151A (pt) Formulações galênicas de rápida desagregação na boca, e, processo de preparação das mesmas
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
DE60016614D1 (de) Zusammensetzungen zur abgabe osteogener proteine
NZ500589A (en) Leptin (ob protein) and active fractions and fragments thereof as inhibitors of tumor cell proliferation
PT98371A (pt) Processo para a preparacao de derivados 6-alcoxi de arabinofuranosil-guanina e de composicoes farmaceuticas que os contem
GR3006815T3 (es)
HU901085D0 (en) Process for producing substituted benzimidazole and pharmaceutical preparatives containing it
SE9402880D0 (sv) New peptide derivatives
CA2063273A1 (en) Surfactant compositions and methods
GB2328872B (en) Method for preparing pharmaceutical formulations
IT1255076B (it) Microsfere biodegradabili ad uso farmaceutico e cosmetico
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NO960525L (no) Terapeutisk preparat
RU94040865A (ru) Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью
HUP9802605A2 (hu) 1,2,4-Benzotriazin-oxid-származékokat tartalmazó orális adagolású gélkapszula gyógyszerkészítmények
AU7533394A (en) Antiacid pharmaceutical composition in the form of a suspension based on sucralphate gel